High Amylose Maize Starch for Treatment of Cholera (RESTORS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01823952|
Recruitment Status : Terminated (The study was closed early due to slow enrollment.)
First Posted : April 4, 2013
Last Update Posted : April 4, 2014
A randomized, double-blind trial in adult males with acute dehydrating diarrhea of cholera comparing the safety, tolerability and efficacy of HAMS HO-ORS, HAMS 2.5% Acetate HO-ORS, HAMS 6% Acetate HO-ORS and HO-ORS.
The primary hypothesis is that at least one of the hypo-osmolar ORS containing high amylose maize starch 6% acetate (HAMSA6-HO-ORS), hypo-osmolar ORS containing high amylose maize starch 2.5% acetate (HAMSA2.5-HO-ORS) and a hypo-osmolar ORS containing high amylose maize starch (HAMS-HO-ORS), will significantly reduce diarrhea duration compared with hypo-osmolar (HO) ORS.
Specifically, the investigators expect that HAMSA6 will be the most effective preparation.
|Condition or disease|
- Burden: Watery diarrhea including cholera continues to be a major cause of childhood mortality in developing countries, with an estimated 1.5 million children dying each year. This figure has greatly reduced from approximately 5 million diarrheal deaths annually 20 years ago, a phenomenon often attributed to the utilization of oral rehydration solution (ORS).
- Knowledge Gap: ORS is very effective in correcting dehydration and reducing mortality, but is not adequately used in many countries, partly due to the fact that it does not reduce diarrhea. The physiological basis for ORS is that glucose-stimulated sodium and fluid absorption is not inhibited by cyclic 3',5'-adenosine monophosphate (cAMP) and other diarrhea mediators which inhibit sodium chloride absorption. The conventional glucose-based ORS does not reduce duration or severity of diarrhea and may in fact paradoxically increase fecal fluid losses. Advances in ORS composition have included the universal adoption of hypo-osmolar ORS (HO-ORS) in 2003. Recent technological innovations have led to the use of amylase-resistant starches and their modifications in the treatment of diarrhea. Short chain fatty acids (SCFA), which are produced in colon from these non-absorbed carbohydrates, enhance sodium absorption. An orally administered, non-absorbed starch (i.e., one resistant to digestion by amylase) significantly reduced fecal fluid loss and the duration of diarrhea in patients with cholera.
- Relevance: Efforts are continuing to improve the efficacy of oral rehydration solution. As glucose stimulates sodium and water absorption in small intestine, short chain fatty acids (SCFAs) stimulate sodium and water absorption in the colon. In cholera, colonic function is also impaired due to the lack of SCFAs. The main source of SCFAs is the unabsorbed carbohydrates that are fermented in the colon by the colonic bacteria. The maize starch contains substantial amount of amylase resistant starch that escapes digestion and absorption in the small intestine and is fermented in the colon, liberating SCFAs. We expect that our experimental ORS containing maize starch will reduce the severity (stool volume) and enhance recovery (reduce duration) of diarrhoea.
|Study Type :||Observational|
|Actual Enrollment :||106 participants|
|Official Title:||Phase 2, Single Centre, Randomized, Double-blind Study Conducted in Adult Males With Acute Dehydrating Diarrhea Due to Cholera With the Aim Being to Select One or More of the Three Fermentable Starches (FS) for an FS-HO-ORS Formulation.|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||February 2014|
- Duration of Diarrhea [ Time Frame: 12 hrs w/o diarrhoea, up to max of 96 hrs ]
Duration of diarrhea during the study period (defined as time from randomisation to the last watery stool preceding two soft/formed stools or a 12 hour period without diarrhea, up to a maximum of 96 hours)
- Stool output and fluid intake rate [ Time Frame: 0 to 96 hrs ]
- Total output of watery stool (g/kg body weight)
- Weight of watery stool
- Intake of oral fluids including ORS and plain water in mL/kg from time of randomization to the first soft/formed stool or 48 hours of treatment with study products, whichever is sooner
- Proportion of patients who vomit in the first 24 hours
- Proportion of patients who require unscheduled intravenous fluids post randomization
- Amount (mL/kg) of unscheduled intravenous fluids required post randomization
- Proportion of patients with diarrhea beyond 48 hours
- Safety & Tolerability as measured by adverse events, vital signs and lab parameters [ Time Frame: Approximately 24 hours after randomization ]
- Proportion of patients with biochemical and symptomatic hyponatremia
- Proportion of patients with adverse events deemed possibly or definitely related to treatment with the investigational products
- Proportion of patients with abnormal biochemical and haematological values (any grade 3 as per CTCAE version IV criteria or above)
- Proportion of patients with serious adverse events deemed possibly or definitely related to treatment with investigational products
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01823952
|Dhaka Hospital - icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh)|
|Mohakhali, Dhaka, Bangladesh, 1212|
|Principal Investigator:||Nur H Alam, MD MBBS||International Centre for Diarrhoeal Disease Research, Bangladesh|